|Bid||252.88 x 800|
|Ask||263.00 x 900|
|Day's range||256.95 - 259.92|
|52-week range||212.40 - 317.17|
|Beta (5Y monthly)||1.03|
|PE ratio (TTM)||12.40|
|Earnings date||26 Oct 2022 - 31 Oct 2022|
|Forward dividend & yield||2.88 (1.11%)|
|Ex-dividend date||17 Aug 2022|
|1y target est||303.69|
Ladies and gentlemen, thank you for standing by, and welcome to the Labcorp Second quarter 2022 Earnings Call. With me today are Adam Schechter, chairman and chief executive officer; and Glenn Eisenberg, executive vice president and chief financial officer. This morning, in the investor relations section of our website at www.labcorp.com, we posted both a press release and an investor relations presentation with additional information on our business and operations, which includes a reconciliation of the non-GAAP financial measures to the GAAP financial measures discussed during today's call, as well as a presentation on additional information on the spin-off of the clinical development business.
LabCorp (LH) posts better-than-expected earnings in the second quarter and demonstrates continued strength in the organic Base Business.
LabCorp (LH) delivered earnings and revenue surprises of 6.21% and 3.19%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?